ADMA Biologics faces securities fraud probe after 29% stock plunge over alleged channel stuffing.

ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for allegedly inflating its 2025 revenue growth through channel stuffing, a practice where excess product was pushed to distributors to falsely boost sales figures. This claim surfaced after a report by Culper Research revealed the company’s real revenue likely declined by 3%, not grew 20% as reported. The stock price dropped 29% following the report, prompting legal action for investors who suffered losses. Investors are encouraged to seek legal advice as the investigation continues.